Wong D T, Threlkeld P G, Robertson D W
Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285.
Neuropsychopharmacology. 1991 Aug;5(1):43-7.
The new antidepressant drugs, fluoxetine (and its enantiomers), citalopram, indalpine, paroxetine, and femoxetine show relatively weak affinities for 5-HT receptors as measured by radioligand binding to 5-HT-1(A,B,C and D), 5-HT-2, and 5-HT-3 subtypes. Fluoxetine and R(-)-fluoxetine, at near micromolar concentrations, inhibit 3H-mesulergine binding to 5-HT-1C receptors in bovine choroid plexus, and the R(-) enantiomer is 23 times more potent than the S(+) enantiomer. However, the near nanomolar potencies of these drugs as inhibitors of 5-HT uptake most likely account for their pharmacologic effects in animals.
新型抗抑郁药物,氟西汀(及其对映体)、西酞普兰、茚达品、帕罗西汀和非莫西汀,通过放射性配体与5-HT-1(A、B、C和D)、5-HT-2和5-HT-3亚型结合测定,显示出对5-HT受体的亲和力相对较弱。氟西汀和R(-)-氟西汀在接近微摩尔浓度时,抑制3H-美舒麦角碱与牛脉络丛中5-HT-1C受体的结合,且R(-)对映体的效力比S(+)对映体强23倍。然而,这些药物作为5-HT摄取抑制剂的近纳摩尔效力很可能解释了它们在动物体内的药理作用。